EMA Recommends Granting a Marketing Authorisation for Catumaxomab By Ogkologos - November 12, 2024 700 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the intraperitoneal treatment of malignant ascites Source RELATED ARTICLESMORE FROM AUTHOR Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for Patients with Metastatic Hormone-Sensitive Prostate Cancer Metastatic Breast Cancer: ESMO Living Guideline EMA Recommends Extension of Indications for Datopotamab Deruxtecan MOST POPULAR Four randomized prospective degree compared 90 days regarding neoadjuvant ADT observed... July 21, 2023 FDA Grants Traditional Approval to Selpercatinib for RET Fusion-positive Thyroid Cancer July 2, 2024 Wine Racks and the Mystery of Survival September 16, 2022 School Teacher’s Breast Cancer Journey Inspired Her to Move to Australia... February 17, 2020 Load more HOT NEWS A Better Biomarker for Cancer Immunotherapy? Her Massive Weight Loss Helped Her Feel A Lump In Her... Not Old Enough for Breast Cancer, She Demanded a Mammogram Anyway... How Some Brain Tumors Hijack the Mind to Grow
